{"success":true,"data":{"pressRelease":{"id":"172655","rtpr_id":"nGNX3dBnbh-20261019","ticker":"SPRC","exchange":"NASDAQ","all_tickers":["SPRC"],"title":"SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications","author":"Globe Newswire","published_at":"2026-10-19T12:35:00.131Z","article_body":"TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:\nSPRC) (“Company” or “SciSparc”), announced that it will shift its\nstrategic focus toward Agentic AI-powered technologies, including\ncybersecurity and finance technologies.\n\nBuilding on its previously announcements from October 15, decision on July 27,\n2026 to target the Agentic AI market and the announcement on August 26, 2026\nof the establishment of its Scientific Advisory Board for AI and\nCybersecurity, the Company intends to evaluate technologies, companies and\nbusiness opportunities across the Agentic AI ecosystem, with a focus on\napplications such as in cybersecurity and finance technologies.\n\nAgentic AI refers to artificial intelligence systems designed to autonomously\nplan and execute tasks to achieve defined objectives. SciSparc aims to build\non its scientific and technical foundation to identify opportunities in these\nmarkets and assess potential avenues for establishing its presence in the\nsector.\n\nThe Company will continue to evaluate opportunities in the field as it pursues\nits strategic shift. There can be no assurance that these efforts will result\nin any transaction, commercial agreement or revenue-generating activity for\nthe Company.\n\nAbout SciSparc Ltd. (Nasdaq: SPRC):\n\nThe Company, through its subsidiary NeuroThera, engages in clinical-stage\npharmaceutical developments. SciSparc’s focus is on creating and enhancing a\nportfolio of technologies and assets based on cannabinoid pharmaceuticals.\nWith this focus, the Company, together with its subsidiary NeuroThera, is\ncurrently engaged in the following drug development programs based on THC\nand/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome,\nfor the treatment of Alzheimer's disease and agitation; and SCI-210 for the\ntreatment of autism spectrum disorder and status epilepticus. The Company,\nthrough NeuroThera, also owns a controlling interest in a subsidiary whose\nbusiness focuses on the sale of hemp seed oil-based products on\nthe Amazon.com\n(https://www.globenewswire.com/Tracker?data=XQ8rO7RdOhe3Dn4ZcUx-G3qCzwuHT4StZq3YKqPx6BLb_sh6ZYMlYymEaJ0_OvH_Oj2dEzeO_DO-LZl1UF3hCo9b01-klI9BmtfvpYeU9UG_BTrUjxgrn_EyvXMu8KShid2I1bb5nLi9a5rR2Fu7s5cdp9MmKMMP91jTWQJXPF3sL1UBCTtLML4q0T86IHA7TA3km1B1Kg6VtmGpDcgkOxI0FhFTfGuQtzxIit04JmUf_r1BBs9kLWfA1x4sHJT8gACNANKonfgMjUbO9MRZVNK7MTqGwONkloOURffbzyYbnFI1-BJxby-tJaPs_lV-BRGFtVV8MpU6zlCKQeBj-FxSpcrS75fvVvzRodMDs-4dT_19LGZYH3Odz-HAZk5TMekjdfdEgJX1PryCnRR410ueZksFaIyH9ALD-EoAtZE=) Marketplace.\n\nForward-Looking Statements:\n\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995 and other Federal securities laws. For example, SciSparc uses\nforward-looking statements when it discusses its planned shift in strategic\nfocus toward Agentic AI-powered technologies, including cybersecurity and\nfinance technologies; its intention to evaluate technologies, companies and\nbusiness opportunities across the Agentic AI ecosystem; its aim to build on\nits scientific and technical foundation to identify opportunities in these\nmarkets and assess potential avenues for establishing its presence in the\nsector; and its plans to continue evaluating opportunities as it pursues its\nstrategic shift. The Company may ultimately not identify any opportunities in\nthe agentic AI field and may not ultimately realize the opportunities\ncontemplated by its strategic shift into the field. Because such statements\ndeal with future events and are based on SciSparc’s current expectations,\nthey are subject to various risks and uncertainties and actual results,\nperformance or achievements of SciSparc could differ materially from those\ndescribed in or implied by the statements in this press release. The\nforward-looking statements contained or implied in this press release are\nsubject to other risks and uncertainties, including those discussed under the\nheading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed\nwith the SEC on April 29, 2026, and in subsequent filings with the U.S.\nSecurities and Exchange Commission. Except as otherwise required by law,\nSciSparc disclaims any intention or obligation to update or revise any\nforward-looking statements, which speak only as of the date they were made,\nwhether as a result of new information, future events or circumstances or\notherwise.\n\nInvestor Contact:\n\nIR@scisparc.com\nTel: +972-3-6167055\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3dBnbh-20261019","title":"SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications","author":"Globe Newswire","ticker":"SPRC","created":"2026-10-19T12:35:00.131Z","tickers":["SPRC"],"exchange":"NASDAQ","article_body":"TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:\nSPRC) (“Company” or “SciSparc”), announced that it will shift its\nstrategic focus toward Agentic AI-powered technologies, including\ncybersecurity and finance technologies.\n\nBuilding on its previously announcements from October 15, decision on July 27,\n2026 to target the Agentic AI market and the announcement on August 26, 2026\nof the establishment of its Scientific Advisory Board for AI and\nCybersecurity, the Company intends to evaluate technologies, companies and\nbusiness opportunities across the Agentic AI ecosystem, with a focus on\napplications such as in cybersecurity and finance technologies.\n\nAgentic AI refers to artificial intelligence systems designed to autonomously\nplan and execute tasks to achieve defined objectives. SciSparc aims to build\non its scientific and technical foundation to identify opportunities in these\nmarkets and assess potential avenues for establishing its presence in the\nsector.\n\nThe Company will continue to evaluate opportunities in the field as it pursues\nits strategic shift. There can be no assurance that these efforts will result\nin any transaction, commercial agreement or revenue-generating activity for\nthe Company.\n\nAbout SciSparc Ltd. (Nasdaq: SPRC):\n\nThe Company, through its subsidiary NeuroThera, engages in clinical-stage\npharmaceutical developments. SciSparc’s focus is on creating and enhancing a\nportfolio of technologies and assets based on cannabinoid pharmaceuticals.\nWith this focus, the Company, together with its subsidiary NeuroThera, is\ncurrently engaged in the following drug development programs based on THC\nand/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome,\nfor the treatment of Alzheimer's disease and agitation; and SCI-210 for the\ntreatment of autism spectrum disorder and status epilepticus. The Company,\nthrough NeuroThera, also owns a controlling interest in a subsidiary whose\nbusiness focuses on the sale of hemp seed oil-based products on\nthe Amazon.com\n(https://www.globenewswire.com/Tracker?data=XQ8rO7RdOhe3Dn4ZcUx-G3qCzwuHT4StZq3YKqPx6BLb_sh6ZYMlYymEaJ0_OvH_Oj2dEzeO_DO-LZl1UF3hCo9b01-klI9BmtfvpYeU9UG_BTrUjxgrn_EyvXMu8KShid2I1bb5nLi9a5rR2Fu7s5cdp9MmKMMP91jTWQJXPF3sL1UBCTtLML4q0T86IHA7TA3km1B1Kg6VtmGpDcgkOxI0FhFTfGuQtzxIit04JmUf_r1BBs9kLWfA1x4sHJT8gACNANKonfgMjUbO9MRZVNK7MTqGwONkloOURffbzyYbnFI1-BJxby-tJaPs_lV-BRGFtVV8MpU6zlCKQeBj-FxSpcrS75fvVvzRodMDs-4dT_19LGZYH3Odz-HAZk5TMekjdfdEgJX1PryCnRR410ueZksFaIyH9ALD-EoAtZE=) Marketplace.\n\nForward-Looking Statements:\n\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995 and other Federal securities laws. For example, SciSparc uses\nforward-looking statements when it discusses its planned shift in strategic\nfocus toward Agentic AI-powered technologies, including cybersecurity and\nfinance technologies; its intention to evaluate technologies, companies and\nbusiness opportunities across the Agentic AI ecosystem; its aim to build on\nits scientific and technical foundation to identify opportunities in these\nmarkets and assess potential avenues for establishing its presence in the\nsector; and its plans to continue evaluating opportunities as it pursues its\nstrategic shift. The Company may ultimately not identify any opportunities in\nthe agentic AI field and may not ultimately realize the opportunities\ncontemplated by its strategic shift into the field. Because such statements\ndeal with future events and are based on SciSparc’s current expectations,\nthey are subject to various risks and uncertainties and actual results,\nperformance or achievements of SciSparc could differ materially from those\ndescribed in or implied by the statements in this press release. The\nforward-looking statements contained or implied in this press release are\nsubject to other risks and uncertainties, including those discussed under the\nheading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed\nwith the SEC on April 29, 2026, and in subsequent filings with the U.S.\nSecurities and Exchange Commission. Except as otherwise required by law,\nSciSparc disclaims any intention or obligation to update or revise any\nforward-looking statements, which speak only as of the date they were made,\nwhether as a result of new information, future events or circumstances or\notherwise.\n\nInvestor Contact:\n\nIR@scisparc.com\nTel: +972-3-6167055\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-19T12:35:00.178351595Z","server_sent_at_ms":1792413300178},"received_at":"2026-10-19T12:35:00.313Z","source_url":null},"analysis":{"id":"160775","press_release_id":"172655","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["micro-cap pivoting from biotech to AI with no disclosed capital, technology, or partners","explicit no-assurance language: shift may not produce any transaction or revenue"],"eventType":"other","narrative":"SciSparc announced a strategic shift toward Agentic AI technologies, targeting applications in cybersecurity and finance.\n\nThe company will evaluate technologies, companies, and business opportunities across the Agentic AI ecosystem, building on its October 15 and July 27 announcements and its AI Scientific Advisory Board formed August 26.\n\nThe release contains no commitments or figures and explicitly cautions that the efforts may not result in any transaction, agreement, or revenue-generating activity. SciSparc remains a clinical-stage cannabinoid pharmaceutical developer through its NeuroThera subsidiary.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"AI pivot announcement with no substance yet -- watch for concrete acquisitions or partnerships before crediting the narrative."},"keyFigures":{},"namedEntities":{"people":[],"products":["SCI-110","SCI-210"],"companies":[{"name":"SciSparc Ltd.","ticker":"SPRC","relationship":"filer"},{"name":"NeuroThera","relationship":"subsidiary"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Announces only an intention to evaluate Agentic AI opportunities in cybersecurity and finance; the release explicitly states there may be no transaction or revenue. No figures, deals, or binding commitments."},"tickerRelevance":{"others":[],"primary":"SPRC"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"strategic-pivot-announcement-no-deal","figuresDisclosed":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SciSparc announced a strategic shift toward Agentic AI technologies, targeting applications in cybersecurity and finance.\n\nThe company will evaluate technologies, companies, and business opportunities across the Agentic AI ecosystem, building on its October 15 and July 27 announcements and its AI Scientific Advisory Board formed August 26.\n\nThe release contains no commitments or figures and explicitly cautions that the efforts may not result in any transaction, agreement, or revenue-generating activity. SciSparc remains a clinical-stage cannabinoid pharmaceutical developer through its NeuroThera subsidiary.","key_figures":{},"named_entities":{"people":[],"products":["SCI-110","SCI-210"],"companies":[{"name":"SciSparc Ltd.","ticker":"SPRC","relationship":"filer"},{"name":"NeuroThera","relationship":"subsidiary"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-19T12:35:05.784Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"strategic-pivot-announcement-no-deal","figuresDisclosed":false}},"durationMs":null,"modelName":"glm-5.3-flashx"}}